Rhythm Pharmaceuticals Announces Updates on MC4R Pathway Programs at R&D Event
December 06, 2023 07:00 ET
|
Rhythm Pharmaceuticals, Inc.
-- Phase 3 trial evaluating setmelanotide in pediatric patients ages 2-<6yo (N=12) over 52 weeks achieved primary endpoint -- -- Setmelanotide achieved 3.04 mean reduction in BMI-Z score and 18.4...
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
November 13, 2023 16:01 ET
|
Rhythm Pharmaceuticals, Inc.
BOSTON, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families...
Rhythm Pharmaceuticals Reports Third Quarter 2023 Financial Results and Business Update
November 07, 2023 07:00 ET
|
Rhythm Pharmaceuticals, Inc.
-- Third quarter 2023 net revenue from global sales of IMCIVREE® (setmelanotide) of $22.5 million -- -- More than 100 international patients on reimbursed IMCIVREE therapy -- -- Phase 3...
Rhythm Pharmaceuticals Receives Positive CADTH Reimbursement Recommendation for IMCIVREE® (setmelanotide)
November 02, 2023 08:00 ET
|
Rhythm Pharmaceuticals, Inc.
-- CADTH recommends reimbursement for weight management in adult and pediatric patients six years of age and older with obesity due to Bardet-Biedl syndrome (BBS) -- -- Recommendation based on...
Rhythm Pharmaceuticals to Report Third Quarter 2023 Financial Results on Tuesday, November 7, 2023
October 25, 2023 08:00 ET
|
Rhythm Pharmaceuticals, Inc.
BOSTON, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families...
Rhythm Pharmaceuticals Presents Data from its Long-term Extension Study of Setmelanotide Showing Sustained and Deepened BMI Reduction in Patients with Hypothalamic Obesity at One Year at ObesityWeek® 2023
October 17, 2023 16:01 ET
|
Rhythm Pharmaceuticals, Inc.
-- Patients with hypothalamic obesity (n=12) achieved mean BMI reduction of 25.5% at one year on setmelanotide treatment -- -- Three of 11 pediatric patients with hypothalamic obesity achieved...
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
October 13, 2023 16:01 ET
|
Rhythm Pharmaceuticals, Inc.
BOSTON, Oct. 13, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families...
Rhythm Pharmaceuticals Announces Six Abstracts to be Presented at The Obesity Society’s Annual Meeting at ObesityWeek ®
October 10, 2023 08:00 ET
|
Rhythm Pharmaceuticals, Inc.
BOSTON, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families...
Rhythm Pharmaceuticals Presents New Data at ESPE 2023
September 22, 2023 08:00 ET
|
Rhythm Pharmaceuticals, Inc.
BOSTON, Sept. 22, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families...
Rhythm Pharmaceuticals Receives Orphan Drug Designation from European Medicines Agency for Setmelanotide for Treatment of Acquired Hypothalamic Obesity
September 19, 2023 08:01 ET
|
Rhythm Pharmaceuticals, Inc.
BOSTON, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families...